[Diagnostic efficiency of NO/ET-1 and HCY level in severe OSAHS patients with cognitive impairment].
Objective:To investigate the diagnostic efficiency of HCY and NO/ET-1 to cognitive dysfunction in patients with severe obstructive sleep apnea hypopnea syndrome, and to interfere with the cognitive function of severe OSAHS patients. Method: Eighty-six patients with OSAHS were divided into mild group (22 cases), moderate group (23 cases), severe group (41 cases) and healthy physical examination group (50 cases). The levels of serum HCY and NO/ET-1 were compared between the four groups. The Montreal cognitive assessment scale was used to evaluate the incidence of mild cognitive impairment in severe OSAHS group, and the correlation between the level of serum HCY, NO/ET-1 and cognitive function in severe OSAHS group was analyzed. Result:The level of serum HCY in patients with severe OSAHS with cognitive impairment was(32.28±3.92)μmol/L, higher than that of the cognitive moderate group(26.34±4.05)μmol/L, and mild group (18.62±3.29)μmol/L. The level of serum NO/ET-1 in patients with severe OSAHS with cognitive impairment was (0.69±0.19), higher than that of the cognitive moderate group(2.76±0.28), and mild group (3.98±0.37), the difference was statistically significant (P<0.05). In severe group, there was a negative correlation between the level of serum HCY and the score of MoCA and its subscores (P<0.05), and there was a positive correlation between the total scores of NO/ET-1 and MoCA and their subscores (P<0.05), and negative correlation between HCY and NO/ET-1 (P<0.05). The area under the ROC curve of predicting serum HCY and NO/ET-1 levels in severe OSAHS patients with cognitive impairment were 0.788(95%CI0.654-0.921) and 0.770 (95%CI0.642-0.899). Conclusion:Serum HCY and NO/ET-1 were the factors influencing the formation of cognitive impairment in severe OSAHS patients. The level of HCY was negatively correlated with the degree of cognitive impairment, and NO/ET-1 was positively correlated with the degree of cognitive impairment.